English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

BeiGene Completes $75 Million USD Financing

Nov. 14, 2014

On November 14, 2014 BeiGene, an innovative Chinese oncology company focused on developing targeted and immune-oncology therapeutics, announced the successful completion of a financing round of over RMB 450 million ($75 million USD). The round includes initial angel and strategic investors and new investors, such as Hillhouse Capital and CITIC PE, as well as an undisclosed blue chip U.S. public investment fund specializing in life sciences.

Proceeds are to support continued development of targeted oncology candidates, with 5 compounds expected to enter the clinical phase by the end of 2015.